FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
35 letters match. Newest first.
-
DrugsTianjin Healthcare Medical Technology Co., Ltd.
Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.
High risk -
DrugsOrganiCare, LLC / OrganiCare Nature’s Science, LLC
FDA told OrganiCare of Austin, Texas that its HClear for him and FemiClear Genital Herpes Symptoms ointments are unapproved new drugs.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsBabikian Healthcare Products CJSC
FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.
High risk -
DrugsDabur India Limited
FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.
High risk -
DrugsYangzhou Hongshengding Chemical Co., Ltd.
Yangzhou Hongshengding Chemical refused FDA records requests for its over-the-counter drugs, leading to an import alert.
High risk -
DrugsLaboratorios Dr. Collado S.A.
FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
High risk -
DrugsGC America, Inc.
FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.
High risk -
DrugsIDO Pharm Co., Ltd.
IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.
High risk -
DrugsFareva Morton Grove
FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.
High risk -
DrugsLiquidCapsule Manufacturing, LLC
LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.
High risk -
DrugsPrivate Label Skin Care, Inc.
FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.
High risk -
DrugsTaizhou Kangping Medical Science and Technology Co., Ltd.
FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.
High risk -
DrugsNaturich Cosmetique Labs
FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.
High risk -
DrugsCreative Essences, Inc.
FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.
High risk -
DrugsDixon Investments Inc. dba ARI
FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.
High risk -
DrugsNWL Netherlands Services B.V.
FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.
High risk -
DrugsTaizhou Jingshang Cosmetics Technology Co., Ltd.
FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.
High risk -
DrugsAspen Pharmacare Holdings Limited
FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.
High risk -
DrugsRite-Kem Incorporated
FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.
High risk -
DrugsAkron Formulations India Private Limited
Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.
High risk -
DrugsMedOffice Saglik Endustri Anonim Sirketi
FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.
High risk -
FoodAmbaya Gold Health Products, LLC
FDA warned Ambaya Gold Health Products that website and social media claims made its supplements and silver products unapproved new drugs.
High risk -
FoodInmar Supply Chain Solutions, LLC
FDA found severe rodent infestation at Inmar warehouse, adulterating stored foods, over-the-counter drugs, and devices.
High risk -
AnimalKraft Drug
Kraft Drug marketed unapproved antibiotics for aquarium fish and birds as over-the-counter drugs, FDA says.
High risk -
DrugsLex Inc.
FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.
High risk -
DrugsAmazon.com, Inc
FDA warned Amazon that it sold four unapproved drugs claiming to treat molluscum contagiosum, including products marketed for children.
High risk -
DrugsSkyline Herbals Private Limited
FDA warns India's Skyline Herbals after it ignored records requests for OTC drugs including toothpaste; all its drugs hit Import Alert 66-79.
High risk -
DrugsDaxal Cosmetics Private Limited
FDA warns Daxal Cosmetics for refusing records on over-the-counter drugs, including toothpaste, at risk for diethylene glycol and ethylene glycol contamination.
High risk -
DrugsEco Lips, Inc.
FDA warned Eco Lips, Inc. that its over-the-counter sunscreen drug products had serious manufacturing and testing failures.
High risk -
DrugsProfounda, Inc.
FDA warns Profounda about manufacturing quality failures for over-the-counter drugs, including process validation, stability, water system, and glycerin testing.
High risk -
DrugsFei Fah Medical Manufacturing Pte. Ltd.
FDA warned Fei Fah Medical Manufacturing over inadequate stability data, unvalidated test methods, and supplier testing failures for over-the-counter drugs.
High risk -
DrugsNeoteric Cosmetics, Incorporated/Scott’s Liquid Gold, Inc.
FDA warned Neoteric Cosmetics and parent Scott's Liquid Gold that ALPHA Skin Care Dual Action Fade Cream, a hydroquinone skin lightener, is an unapproved and misbranded drug.
Medium -
DrugsDr Retter Ec Wladyslaw Retter
FDA warns Dr Retter Ec Wladyslaw Retter over manufacturing failures for homeopathic drug cream.
High risk -
DrugsGulsah Uretim Kozmetik Sanayi Anonim Sirketi
Turkish OTC drug maker Gulsah failed to test its products and ingredients, and FDA blocked its U.S. imports.
High risk